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Abstract
 
Dendritic cells (DCs), nature’s adjuvant, must mature to sensitize T cells. However, although
the maturation process is essential, it is not yet fully understood at the molecular level. In this
study, we investigated the course of expression of the unique hypusine-containing protein eu-
karyotic initiation factor 5A (eIF-5A), which is part of a particular RNA nuclear export path-
way, during in vitro generation of human DCs. We show that eIF-5A expression is significantly
upregulated during DC maturation. Furthermore, an inhibitor of the hypusine modification,
GC7 (
 
N
 
1
 
-guanyl-1,7-diaminoheptane), prevents CD83 surface expression by apparently inter-
fering with nucleocytoplasmic translocation of the CD83 mRNA and, importantly, signifi-
cantly inhibits DC-mediated T lymphocyte activation. The data presented suggest that CD83
mRNA is transported from the nucleus to the cytoplasm via a specific nuclear export pathway
and that hypusine formation appears to be essential for the maturation of functional DCs.
Therefore, pharmacological interference with hypusine formation may provide a new possibil-
ity to modulate DC function. 
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Introduction
 
Dendritic cells (DCs)
 
1
 
 are specialized to sensitize helper and
killer T cells and thus act as “nature’s adjuvant” in inducing
T cell–mediated immunity (1). Immature DCs capture anti-
gens in the periphery but lack full T cell–stimulatory capac-
ity. In the presence of appropriate stimuli (such as microbial
products and/or inflammatory cytokines), the DCs then
mature. DCs upregulate T cell adhesion and costimulatory
molecules as well as selected chemokine receptors that guide
DC migration into secondary lymphoid organs for priming
of antigen-specific T cells (2). DCs are defined by their po-
tent T cell–stimulatory capacity (e.g., in the allo-MLR) as
well as a characteristic morphology (nonadherent cells with
motile veils) and phenotype (upregulation of CD86 and de
novo expression of CD83; references 3 and 4).
DCs can be generated in vitro either from rare prolifer-
ating CD34
 
1
 
 or frequent, nonproliferating CD14
 
1
 
 mono-
cytic precursors (5–8). The generation of DCs from mono-
cytes under the use of GM-CSF and IL-4 yields homogenous
DC progenitors that are well suited for studying the matu-
ration of DCs in vitro (9).
Eukaryotic initiation factor 5A (eIF-5A) is the only cel-
lular protein known to contain the unusual amino acid hy-
pusine, a modification that appears to be required for cell
proliferation (10, 11). The hypusine modification is a sper-
midine-dependent posttranslational reaction that is cata-
lyzed by two enzymes. This includes the transfer of the
aminobutyl moiety of spermidine to the 
 
e
 
-NH
 
2
 
 group of
lysine at position 50 in eIF-5A by deoxyhypusine synthase
(12–14). The intermediate that is generated is subsequently
hydroxylated by deoxyhypusine hydroxylase (15), resulting
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in the active form of eIF-5A. Although eIF-5A was origi-
nally designated as an “initiation factor” (16, 17), more re-
cent in vitro and in vivo data have demonstrated that eIF-
5A is not an initiator of protein translation (18–20). In fact,
the subsequent finding that eIF-5A is a cellular cofactor of
HIV-1 Rev and HTLV-I Rex transactivator proteins sug-
gested an entirely different eIF-5A activity (21–24). Both
Rev and Rex are nucleocytoplasmic shuttle proteins that
mediate the nuclear export of incompletely spliced and un-
spliced viral mRNAs (25, 26). Thus, eIF-5A appears to be
part of a specific nuclear export pathway that is exploited
by the Rev/Rex class of retroviral RNA transport factors.
This notion is further supported by the finding that, in
yeast, eIF-5A affects the decay of specific mRNAs that are
transported from the nucleus to their cytoplasmic site of
degradation (20, 27) and, more recently, that eIF-5A is a
high-copy suppressor of transport-deficient TATA binding
protein mutants (28). Furthermore, the eIF-5A protein it-
self has been shown to accumulate at the nucleoplasmic site
of nuclear pore complexes to interact with the general nu-
clear export receptor CRM1 and to translocate from the
nucleus to the cytoplasm in mammalian cells (29).
Investigation of eIF-5A mRNA levels in human cells re-
vealed that eIF-5A is constitutively expressed in cell lines as
well as in various tissues (30). In contrast, the eIF-5A gene
appears to be subject to distinct regulation in primary lym-
phoid cells. In particular, eIF-5A gene expression is consti-
tutively low but inducible with T lymphocyte–specific
stimuli in human PBMCs (30). The combined data suggest
that the hypusine-containing protein eIF-5A fulfills a spe-
cific and presumably essential function during activation
and/or proliferation of primary human blood cells.
In this work, we investigated the expression level of the
hypusine-containing protein eIF-5A during maturation of
primary human DCs. Using an inhibitor of hypusine mod-
ification, we are able to show that formation of hypusine is
required for the expression of the DC-specific molecule
CD83 and the full stimulatory activity of mature DCs,
demonstrating a potentially novel approach by which to in-
terfere with DC function.
 
Materials and Methods
 
Cell Culture Medium.
 
Cells were cultured using a standard
medium (referred to as 1% human plasma medium), which con-
sisted of RPMI 1640 (BioWhittaker) supplemented with glutamine
(300 
 
m
 
g/ml) (BioWhittaker), penicillin/streptomycin (20 
 
m
 
g/
ml), 10 mM Hepes, pH 7.5 (Sigma-Aldrich), and 1% heat-inacti-
vated (56
 
8
 
C; 30 min) human plasma from a single AB donor, ob-
tained from the Department of Transfusion Medicine, Erlangen,
Germany.
 
Generation of DCs.
 
PBMCs (5 
 
3
 
 10
 
7
 
) were isolated from
buffy coats by sedimentation in Ficoll-hypaque (Amersham Phar-
macia Biotech) and seeded onto IgG-coated (10 
 
m
 
g/ml 
 
g
 
-globu-
lin from Cohn fraction; Sigma-Aldrich) 100 mm-culture dishes
and incubated at 37
 
8
 
C in 5% CO
 
2
 
. After 1 and 7 h of incubation,
nonadherent cell fractions were harvested, and the remaining ad-
herent cells were further cultured in 1% human plasma medium
 
supplemented with the cytokines GM-CSF (800 U/ml) and IL-4
(1,000 U/ml). Fresh medium (5 ml) containing 4,000 U GM-
CSF and 5,000 U IL-4 was added to the culture dish at day 3 of
this incubation period. On day 4 or 5, nonadherent cells were
collected, counted, and transferred into new dishes at a density of
0.3–0.5 
 
3
 
 10
 
5
 
 cells/ml. For final DC maturation, 1% human
plasma medium was supplemented with TNF-
 
a 
 
(25 ng/ml),
prostaglandin E
 
2
 
 (PGE
 
2
 
; 1 ng/ml), GM-CSF (400 U/ml), and IL-4
(500 U/ml) (31). In the studies using the hypusine inhibitor GC7
(
 
N
 
1
 
-guanyl-1,7-diaminoheptane), immature DCs were pretreated
at day 4 or 5 with GC7 at a concentration of 1 
 
m
 
M for 10 min
before addition of the final maturation medium.
 
Cytokines and GC7.
 
Recombinant human (rh)GM-CSF and
GC7 (32) were obtained from Novartis Research Institute, rhIL-4
from Genzyme, rhTNF-
 
a
 
 from Boehringer, and PGE
 
2
 
 from
Cayman Chemical.
 
FACS
 
®
 
 Analyses.
 
For flow cytometry analyses, mAbs recog-
nizing the following antigens were used: CD83 (Immunotech),
CD80, CD86, CD13, CD68, MHC class I, MHC class II, and
CD95 (Becton Dickinson). The isotype controls IgG1a and
IgG2b were obtained from Becton Dickinson and were run in
parallel. Cell populations were phenotyped with the panel of
mAbs listed above and analyzed on a FACScan™ (Becton Dick-
inson) as described previously (8). Nonviable cells were gated out
on the basis of their light scattering properties.
 
Western Blot Analyses.
 
Cells (0.5 
 
3
 
 10
 
6
 
) were harvested on
days 4, 5, 6, and 7 of the DC generation procedure, washed with
PBS, and solubilized in gel loading buffer (50 mM Tris-HCl, pH
6.8, 2% SDS, 10% glycerol, 5% 
 
b
 
-mercaptoethanol, and 0.1%
bromophenol blue). After SDS-PAGE, the separated proteins
were transferred onto nitrocellulose membranes, and specific an-
tibodies were used to detect eIF-5A (33), histone H1 (StressGen
Biotechnologies), and CD83 as described previously (29).
 
RNA Analyses.
 
CD83 and eIF-5A mRNA levels were ana-
lyzed by PCR. Total cellular RNA from 10
 
6
 
 cells was isolated at
different time points of DC maturation using TRIzol™
 
 
 
Reagent
(GIBCO BRL). Subsequently, the RNA was reverse transcribed
into single-stranded cDNA using AMV reverse transcriptase ac-
cording to the manufacturer’s protocol (Roche Molecular Bio-
chemicals). Serial dilutions of the cDNA preparations were sub-
jected to AmpliTaq
 
®
 
 (Perkin-Elmer) DNA polymerase–mediated
PCR amplification using primer pairs specific for eIF-5A (5
 
9
 
-
GCAGATGACTTGGACTTCGAGACAGG-3
 
9
 
 and 5
 
9
 
-CCT-
TGATTGCAACAGCTGCCTCCTC-3
 
9
 
) and CD83 (5
 
9
 
-GTT-
ATTGGAGGGTGGTGAAGAGAGG-3
 
9
 
 and 5
 
9
 
-GTGAGGAGT-
CACTAGCCCTAAATGC-3
 
9
 
). Amplification of the mRNA
coding for the ribosomal protein S14 served as an internal control
(5
 
9
 
-GGCAGACCGAGATGAATCCTCA-3
 
9
 
 and 5
 
9
 
-CAGGTC-
CAGGGGTCTTGGTCC-3
 
9
 
). The profile for amplification in-
volved 30 cycles of denaturation at 95
 
8
 
C for 60 s, primer anneal-
ing at 55
 
8
 
C for 60 s, and primer extension at 72
 
8
 
C for 90 s. The
reaction products were analyzed on ethidium bromide–stained
2% agarose gels.
Northern blot analysis of 5 
 
m
 
g of total cellular RNA derived
from either DCs or HeLa cells was performed as described previ-
ously (34). CD83-specific transcripts were detected using the ra-
diolabeled synthetic oligonucleotide probe 5
 
9
 
-TCTCCATCCTCT-
CTTCACCACCCTCCAATAAC-3
 
9
 
. To control for comparable
RNA amounts, the filters were stripped and rehybridized using a
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) probe, 5
 
9
 
-
CCATGGTGGTGAAGACGCCAGTGGACTCC-3
 
9
 
.
 
Immunofluorescence Microscopy.
 
2 d after addition of the final
maturation cocktail, cells were harvested and washed with RPMI 
1583
 
Kruse et al.
 
medium. Subsequently, 0.5 
 
3
 
 10
 
6
 
 cells were spun onto poly-
lysine-coated microslides (Menzel-Gläser) for 30 s at 300 rpm us-
ing a cytospin3 centrifuge (Shandon), fixed in 2% paraformalde-
hyde (Merck), and washed three times with PBS and 1% glycerol
(Sigma-Aldrich). Blocking was performed with 1% BSA (Sigma-
Aldrich). Cells were then incubated with primary anti-CD83
mAb, followed by secondary Cy3-conjugated, affinity-purified
goat anti–mouse IgG (Rockland). Reactions were performed for
30 min at ambient temperature. Finally, the slides were washed
five times with PBS, and cells were embedded in Moviol (Calbio-
chem). The samples were analyzed using a ZEISS Axiovert-135
microscope. Images were recorded with a cooled MicroMax
CCD camera (Princeton Instruments) and processed using the IP-
Lab spectrum and Adobe Photoshop software.
 
In Situ Hybridization.
 
12 h after addition of the final matura-
tion cocktail, 0.5 
 
3
 
 10
 
6
 
 untreated or GC7-treated cells were
seeded onto adhesion slides (Bio-Rad) and fixed for 15 min with
3% paraformaldehyde. After washing with PBS, cells were perme-
abilized with 0.5% Triton X-100 for 5 min, washed twice with
PBS, and incubated twice for 10 min with 2
 
3
 
 SSC. For RNA de-
tection, the following digoxigenin-labeled oligonucleotides from
Eurogentec were used: CD83, 5
 
9
 
-TGGTTCTTTCGACGC-3
 
9
 
and 5
 
9
 
-TGTGGACTTGCCCTG-3
 
9
 
; CD86, 5
 
9
 
-ACTGACAAG-
ACGCGG-3
 
9
 
 and 5
 
9
 
-CAAGTATATGGGCCG-3
 
9
 
. For hybrid-
ization, cells were incubated in hybridization solution containing
10 ng/
 
m
 
l of each labeled oligo, 25% deionized formamide, 1 
 
m
 
g/
 
m
 
l 
 
Escherichia coli
 
 tRNA (Sigma-Aldrich), 2
 
3 
 
SSC, 0.5% BSA, and
10% dextran sulfate for 16 h at 42
 
8
 
C in a humidified chamber.
Unbound probe was removed by two 30-min washes in 2
 
3 
 
SSC
and one 15-min wash in 1
 
3 
 
SSC. Subsequently, cells were
washed with 0.1% Triton X-100 in PBS and blocked with 1%
BSA for 30 min. Hybrids were stained for 30 min with primary
 
a
 
-digoxigenin mAb (Roche Molecular Biochemicals). After ex-
tensive wash steps in PBS, cells were incubated with the appropri-
ate secondary antibody coupled to Cy3 fluorophore (Biotrends).
The cells were then treated with 1 
 
m
 
g/ml DAPI (4
 
9
 
,6-diamidino-
2-phenylindole; Roche Molecular Biochemicals) in PBS, washed
again several times in PBS, and mounted in Mowiol. Samples
were analyzed by immunofluorescence microscopy as described
above.
 
Allogeneic MLR.
 
CD4
 
1
 
 and CD8
 
1
 
 T cells were isolated from
buffy coats and stimulated with mature allogeneic DCs, which
were either untreated or pretreated with GC7 (end concentration
of 1 
 
m
 
M) during DC maturation. T cells (2 
 
3
 
 10
 
5
 
 per well) and
DCs were cocultivated for 4 d in 200 
 
m
 
l RPMI, supplemented
with 5% human serum from a single AB donor in 96-well cell
culture dishes. Then, cells were pulsed with [
 
3
 
H]thymidine (1
 
m
 
Ci/well; Amersham Pharmacia Biotech) for 8–16 h. The cul-
ture supernatants were harvested onto glass fiber filtermates using
an IH-110 harvester (Inotech), and filters were counted in a 1450
microplate counter (Wallac).
 
Results
 
The Hypusine Inhibitor GC7 Affects CD83 Surface Expres-
sion in DCs. 
 
To investigate eIF-5A expression during DC
maturation, we generated human DCs in vitro, following a
modified two-step protocol (31). The mature DCs gener-
ated by this protocol displayed the specific parameters that
are routinely used to define mature DCs. Mature DCs are
characterized by the typical morphology of nonadherent cells,
a distinct cytofluorographic profile (HLA-DR
 
111
 
CD86
 
11
 
CD14
 
2
 
CD83
 
11
 
p55
 
11
 
), and a highly potent stimulatory
capacity in allogeneic MLRs at DC/T cell ratios of 
 
#
 
1:300.
Furthermore, these cells stably maintained the DC pheno-
type when cultured for an additional 1–2 d in the absence
of exogenously added cytokines (also known as the “wash-
out” or “stability” test; reference 8).
We first examined eIF-5A levels by Western blot analysis
using total protein extracts from various stages of DC gen-
eration. As shown in Fig. 1 B, the eIF-5A protein, migrat-
ing at a relative molecular mass of 
 
z
 
18 kD (35, 36), was
barely detectable within the initial days of cell culture (lanes
1 and 2). Clearly, a significant increase in eIF-5A protein
was detected toward the end, namely at days 6 and 7, of the
maturation period (Fig. 1 B, lane 3 and 4). As eIF-5A may
be required for functional expression of DC-specific mole-
cules, identical protein blots were subsequently probed
with antibodies directed against CD83, a molecule of un-
known function that is, nonetheless, one of the best cell
surface markers for mature DCs (37). These analyses dem-
onstrated that the time course of CD83 protein expression
followed similar kinetics to those of eIF-5A during DC
maturation (compare Fig. 1, A and B). This observation
could mean that the expression of CD83 may depend on
eIF-5A function.
The 154–amino acid eIF-5A protein is unique because it
is the only cellular protein known to date to contain the
unusual amino acid hypusine (10, 11). This enzyme-cata-
lyzed posttranslational modification is essential for eIF-5A
function and can be blocked in cell culture with deoxyhy-
pusine synthase inhibitors (38–40). In particular, the low-
molecular-mass drug GC7 has been shown to be the most
specific and potent inhibitor, with a 
 
K
 
i
 
 value 
 
,
 
10 nm (32,
38). Therefore, we next investigated the effect of GC7 on
CD83 surface expression. As seen in Fig. 2, CD83-specific
immunofluorescence analysis revealed that although CD83
surface expression was absent on day 5, it was easily detect-
able on day 7 of DC maturation (compare panels A and B),
Figure 1. Detection of eIF-
5A and CD83 protein expression
during in vitro generation of hu-
man DCs by Western blot analy-
sis. Cellular protein extracts from
different DC generation time
points (indicated at the bottom)
were resolved by SDS-PAGE,
transferred to nylon membranes,
and probed with (A) CD83-spe-
cific, (B) eIF-5A–specific, or (C)
histone H1–specific (loading con-
trol) antibodies.1584 Inhibition of CD83 Surface Expression in Dendritic Cells
reflecting the data obtained in the experiments using total
cell protein extracts (Fig. 1 A). In sharp contrast, when
GC7 was added to the cell culture medium on day 5 (1
mM), a strong decrease in CD83-specific immunofluores-
cence was observed at the end of the maturation period
(day 7, Fig. 2 D). A control experiment demonstrated that
DMSO (solvent for GC7) alone had no significant inhibi-
tory effect on CD83 surface expression (Fig. 2 C). Quanti-
fication of the fluorescence signals (Fig. 2 E) confirmed that
the presence of the hypusine modification inhibitor GC7
indeed reduced the surface expression of CD83 at least
fivefold during the in vitro generation of human DCs.
For further characterization of the effect of GC7 on DC
precursors, we next extended our studies with GC7 to
other cell surface molecules expressed on mature DCs.
FACS® analyses confirmed that the cell surface expression
of CD83 was significantly reduced (Fig. 3 A). In contrast,
CD95 (Fig. 3 C), a molecule involved in programmed cell
death (41), the MHC class I and II molecules (Fig. 3, D and
E), CD13 (Fig. 3 B), which is a protein constitutively ex-
Figure 2. Effect of GC7 on CD83 cell surface expression. Human DC
precursors were subjected to CD83-specific indirect immunofluorescence
analysis. (A) No significant CD83 surface expression was detectable in
immature DCs (indicated by asterisks) at day 5. (B) Analysis of mature
cells at day 7 demonstrated a strong CD83 surface expression. (C) Com-
parable signals were detected when DMSO was present in the cell cul-
tures. (D) Exposure of precursor cells to the hypusine inhibitor GC7 (1
mM in DMSO) demonstrated a significant inhibitory effect on CD83 cell
surface expression. (E) Quantification of the CD83-specific fluorescence
signals shown in A–D.
Figure 3. FACS® analyses of untreated or GC7-treated DCs. Left panels
show the typical phenotype of untreated mature DCs. Right panels show
the effect of GC7 treatment. (A) GC7 strongly reduced CD83 cell surface
expression. No significant GC7 effect on cell surface expression was ob-
served in case of CD13 (B), CD95 (C), MHC class I and II molecules (D
and E, respectively), and CD68 (H). Only a minimal reduction was ob-
served for CD80 and CD86 cell surface expression (F and G, respectively).1585 Kruse et al.
pressed on myeloid cells (42), and CD68 (Fig. 3 H), a mol-
ecule that discriminates between DCs and macrophages
(43), were not affected by GC7 treatment. Furthermore,
expression of the costimulatory molecules CD80 and
CD86 was only slightly reduced (Fig. 3, F and G). Impor-
tantly, when fully mature DCs were treated with GC7, no
alteration in the expression of the cell surface molecules an-
alyzed above was observed, indicating that only immature
DC precursors are sensitive to GC7. Finally, GC7 did not
induce necrosis or apoptosis as determined by propidium
iodide and annexin V staining (data not shown).
Taken together, the data presented demonstrate that the
biosynthesis of the hypusine-containing protein eIF-5A is
specifically regulated during DC maturation and that hypu-
sine formation appears to be required for surface expression
of the DC marker molecule CD83.
GC7 Affects the Intracellular Distribution of CD83-specific
mRNA in DCs.  To obtain an insight into how GC7 in-
terferes with CD83 expression, we next prepared total cel-
lular RNA from immature and mature DCs that were cul-
tured in the presence or the absence of GC7. Subsequently,
these RNAs were reverse transcribed into single-stranded
cDNAs, which were then analyzed by PCR using specific
oligonucleotide primer pairs. Amplification of ribosomal
protein S14 RNA-derived sequences served as an internal
control, and serial 10-fold dilutions of the input templates
(cDNAs) indicated linear PCR kinetics. The relative levels
of the investigated mRNAs were comparable, irrespective
of whether or not GC7 or the solvent control DMSO was
present in the cell cultures (Fig. 4 A). This highly sensitive
RNA assay also revealed that CD83-specific mRNA is al-
ready detectable on day 5 of the DC maturation period
and, most importantly, that GC7 treatment did not alter
the CD83 mRNA levels. We next subjected total cellular
RNA isolated from untreated or GC7-treated (days 5–8)
DCs to CD83-specific Northern blot analysis (44), thereby
demonstrating again that GC7 does not have a significant
influence on the overall CD83 mRNA level in DCs (Fig. 4
B, lanes 1 and 2). As expected, no CD83 messages were
present in total RNA derived from HeLa cells (Fig. 4 B,
lane 3). Taken together, these data suggested that CD83
surface expression is blocked by GC7 at the posttranscrip-
tional level.
As the hypusine-containing protein eIF-5A has been
shown to be involved in the nucleocytoplasmic transport of
HIV-1– and HTLV-I–specific mRNAs (21–24), it is con-
ceivable that GC7 may affect the intracellular distribution
of CD83-specific mRNA. This would mean that eIF-5A
activity, which critically depends on the posttranslational
hypusine modification of the eIF-5A precursor, mediates
efficient nuclear export and thereby, indirectly, the transla-
tion of CD83 mRNA.
To test this hypothesis, we next directly examined po-
tential GC7-dependent accumulation of CD83 mRNA in
the cytoplasmic and nuclear compartment of DCs. As only
limited amounts of DCs can be obtained from blood sam-
ples, a direct biochemical fractionation of total cellular
RNA in nuclear and cytoplasmic subfractions was not fea-
sible. We therefore subjected our in vitro–generated DCs
to CD83 mRNA in situ hybridization. The nuclei of fixed
DCs (Fig. 5, K, L, and M) were visualized by DNA stain-
ing using DAPI (Fig. 5, A, B, and C). To prevent the loss
of cells through nonadherence in this type of experiment,
special adhesion slides were used that affect the typical DC
morphology. Inspection of the CD83-specific signals dem-
onstrated that almost comparable levels of CD83 mRNA
accumulate in the DC nucleus and cytoplasm (Fig. 5 D).
However, in the presence of GC7, the CD83 mRNA ap-
pears to be trapped in the nuclear compartment (Fig. 5 E).
This becomes particularly obvious when the respective im-
ages are merged (compare Fig. 5, G and H). Furthermore,
it appears that the CD83 mRNA is not randomly distrib-
uted within the nuclei of GC7-treated cells but tends to ac-
cumulate at distinct subnuclear sites. This GC7 effect is
specific for CD83 mRNAs, since addition of GC7 did not
result in nuclear trapping of CD86-specific messages (Fig. 5
Figure 4. Detection of eIF-5A– and CD83-specific mRNAs. (A) Total
cellular RNA was isolated from untreated, DMSO-treated, and GC7-
treated DC precursors at the indicated time points and reverse tran-
scribed. Using specific oligonucleotide primers, serial dilutions of the re-
spective cDNAs were subjected to PCR and subsequently analyzed by
agarose gel electrophoresis. Amplification of ribosomal protein S14
RNA-specific sequences served as control for input cDNA amounts. The
identities of the various amplification products (indicated at right) were
confirmed by DNA sequence determination (not shown). 2, negative
PCR control; 1, positive PCR control. (B) Northern blot analysis of to-
tal cellular RNA isolated from DCs that were matured in either the ab-
sence (lane 1) or presence (lane 2) of GC7. CD83-specific mRNA species
were detected, irrespective of whether or not GC7 was present in the cell
cultures. In contrast, no CD83 transcripts were detected in total RNA
derived from HeLa cells (lane 3). To control for loading of comparable
quantities of RNA, the filters were stripped and rehybridized using a
probe specific for GAPDH mRNA.1586 Inhibition of CD83 Surface Expression in Dendritic Cells
F). Please note that these data are in good agreement with
the FACS® analyses shown in Fig. 3 G.
These data suggest that CD83 mRNA is transported
from the DC nucleus to the cytoplasm by exploitation of a
specific pathway. Moreover, interference with this pathway
results in nuclear trapping of CD83 mRNA and therefore
in decreased CD83 protein synthesis.
GC7 Inhibits the Ability of DCs to Induce Allogeneic T Cell
Proliferation.  The most distinctive functional characteris-
tic of DCs is their ability to induce a potent T cell response
(45). Therefore, we studied whether or not the observed
GC7 effect on DC surface molecules, and in particular the
prominent inhibition of CD83, also affected the ability of
DCs to induce T cell proliferation in an allogeneic MLR.
As depicted in Fig. 6, mock- or DMSO-treated DCs dis-
played comparable T cell proliferation induction rates in this
experiment. Clearly, GC7 impaired the ability of DCs to
induce a significant T cell response in the MLR. Although
these experiments do not show that CD83 downregulation
alone is responsible for reduced stimulation, the data indi-
cate that hypusine formation is required for DC function.
Discussion
Functional, mature DCs are derived from circulating
precursor cells after a period of maturation (4, 46). During
this period, many activities at the level of gene regulation
take place within the precursor cells which ultimately result
in formation of mature DCs (47). In addition to their func-
tional qualities, DCs are also characterized by the expres-
sion of a specific array of marker molecules. These include
Figure 5. Subcellular localization of CD83 and
CD86 mRNA in DC precursor cells. Images be-
longing to the same experiment are aligned in col-
umns. Mock-treated (CD83: A, D, G, and K) or
GC7-treated (CD83: B, E, H, and L; CD86: C, F,
I, and M) DC precursors were subjected to CD83
mRNA– or CD86 mRNA–specific in situ hybrid-
ization. Nuclei were labeled by DNA staining using
DAPI (A, B, and C). mRNAs were visualized with
digoxigenin-labeled oligonucleotide probes, fol-
lowed by primary a-digoxigenin and appropriate
secondary Cy3-coupled antibodies (D, E, and F).
Comparison of the merged images shows equal dis-
tribution of CD83 mRNA between the nucleus
and the cytoplasm in mock-treated DCs (G). In
contrast, GC7 treatment of DCs results in nuclear
accumulation of CD83 mRNA (H). As shown in
panel I, GC7 treatment of DCs does not result in
nuclear trapping of CD86 mRNA. Corresponding
phase contrast images are shown in K, L, and M.
Figure 6. Effect of GC7 on the ability of DCs to induce allogeneic T
cell proliferation. Mature DCs derived from untreated (s) or DMSO-
treated (h) precursors induce a strong allostimulatory reaction in the pri-
mary allogeneic MLR. In contrast, cells derived from GC7-treated pre-
cursors demonstrate a reduced allostimulatory capacity (j).1587 Kruse et al.
the accessory/costimulatory gene products CD40, CD80,
and CD86 as well as MHC class I and II (1, 3). In particu-
lar, the presence of the CD83 molecule is a well character-
ized marker for fully mature DCs, as CD83 can not be de-
tected on immature DC precursors (37). The functional
significance of CD83 is, however, completely unknown.
In this study, we show that CD83 expression is upregu-
lated during DC maturation and is closely mirrored by the
expression pattern detected for the hypusine-containing
protein eIF-5A. More importantly, our experiments show
that GC7, a highly potent inhibitor of the unique hypusine
modification in eIF-5A, significantly inhibits CD83 surface
expression in these cells. As previously published data have
demonstrated that eIF-5A plays a functional role in HIV-1
Rev- and HTLV-I Rex-mediated nuclear export of retro-
viral mRNAs (21–24), it was tempting to speculate that
GC7 may also interfere with the translocation of the CD83
mRNA across the nuclear envelope in DCs. The notion of
a potential GC7 effect on intracellular CD83 mRNA trans-
port was further supported by the recent finding that eIF-
5A binds the export receptor CRM1 and accumulates
at nuclear pore–associated intranuclear filaments, the site
where initial docking of export substrates to the nuclear
pore complex is believed to occur (29). Thus, the inhibi-
tion of nucleocytoplasmic translocation of CD83 mRNA
by GC7 should indeed result in the observed downregula-
tion of CD83 cell surface expression. In fact, examination
of the intracellular distribution of CD83 mRNA in our
precursor cells demonstrated a marked redistribution of
these transcripts between the subcellular compartments
upon addition of GC7. GC7 clearly prevented efficient cy-
toplasmic accumulation of CD83 mRNA, as the messages
remained trapped in the cell nucleus, an effect that was not
observed for CD86 mRNA. Taken together, these data
suggest that hypusine formation is required for efficient nu-
clear export of CD83 mRNA. Thus, CD83 mRNA ex-
ploits a specific pathway for its transport from the nuclear
site of RNA transcription and processing to the site of
translation in the cytoplasm.
Competition experiments in Xenopus oocytes suggested
that different classes of RNA (e.g., mRNA, rRNA, U-rich
snRNA, and tRNA) are exported from the nucleus by spe-
cific export factors (48). General nuclear export of mRNA
appears to be mediated by a class of abundant RNA bind-
ing proteins termed heterogeneous nuclear ribonucleopro-
teins (hnRNPs; for review see references 49 and 50).
hnRNPs associate with poly(A)1 RNA in the nucleus as
well as in the cytoplasm, and some subsets of hnRNPs have
been shown to shuttle between these cellular compartments
(51). However, little is known about the regulation of nu-
clear export of specific groups of mRNAs. A series of re-
cent studies in which the metabolism of early response gene
(ERG) mRNA subsets was investigated provided new evi-
dence that specifically regulated mRNA export pathways
may indeed exist in mammalian cells (for review see refer-
ence 52). ERG mRNAs encode functionally important
proteins such as protooncoproteins, cytokines, and lym-
phokines that are characterized by a short half-life due to
instability sequences, termed AU-rich elements (AREs).
ARE sequences are commonly found in the 39-untranslated
region of these short-lived mRNAs (53). However, bind-
ing of the HuR (also called HuA) nucleocytoplasmic shut-
tling protein to ARE sequences significantly increases the
stability of ERG mRNAs (54–57) and may subsequently
lead to elevated ERG mRNA levels in the cytoplasm.
Thus, differences in mRNA nuclear export rates can have
pronounced effects on the expression of specific genes, pro-
viding cells with an effective mechanism to quickly respond
to environmental signals. The data presented in this study
also suggest that CD83 mRNA, which does not contain
obvious ARE-rich regions (44), can accumulate in the cy-
toplasm by virtue of a similar mRNA transport mechanism
during DC differentiation. Such a mechanism would assure
the timely and efficient expression of critical DC proteins.
The existence of such a mechanism would indeed be bene-
ficial in the case of CD83. As a result of the specific surface
expression on mature DCs only, CD83 is considered to be
an important protein for DC function, although its precise
activity in DCs remains elusive.
Clearly, the inhibitory effect of GC7 on DC activity can
not be attributed exclusively to the lack of CD83 expres-
sion. We cannot rule out the possibility that GC7 may also
affect the metabolism of additional mRNAs in DCs, which
have not yet been identified. Nevertheless, interference
with eIF-5A function provides a new method to investi-
gate DC function at the molecular level that may ultimately
result in the identification of additional functionally impor-
tant DC proteins. Furthermore, the pharmacological inter-
ference with hypusine formation may also provide a novel
approach to modulate DC activity.
As DCs are able to induce both immunity and tolerance,
they represent a very promising cell type for future im-
mune therapy studies. The elucidation of the mode of ac-
tion of DC-specific molecules, like CD83 on the molecular
level, will not only be important to understand the biology
of DC but also be advantageous for the development of
new therapeutic strategies.
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